US-based diagnostic micro lab provider Ativa Medical raised a $15m series B round yesterday from investors including Ping An Ventures, the corporate venturing arm of insurance company Ping Insurance.
Hermed Capital, an investment fund set up by pharmaceutical firm Fosun Pharma and conglomerate SK Group; Gimdx, a research and development subsidiary of Guangzhou Improve Medical; healthcare diagnostics company LabCorp; laboratory services provider Dian Diagnostics; and health care fund Diamond BioFund also participated in the series B round.
Ativa is working on point-of-care diagnostic technologies that enable health care professionals to take quicker decisions on treatments. The company’s platform requires only a few drops of blood and performs a range of common tests within five minutes.
The capital will support Ativa’s efforts of gaining regulatory approval in the US. As part of the investment, Jiang Zhang, director of Ping An Ventures, will join Ativa’s board of directors.
The company has now secured a total of $23.2m in combined equity funding and debt financing.